Overshooting the annual IP budget puts pressure on the company’s bottom line. Under-spending could negatively impact future budget levels. Effectively managing costs is a crucial step for strategic IP portfolio management. Without good cost control, IP leaders are not well positioned to manage higher-order priorities, like optimizing the agent network, licensing the portfolio and aligning spend with business strategy. To hit budget numbers consistently, IP leaders need the ability to predict their future IP spend accurately.

But trying to predict IP costs accurately is extremely complex. Fees vary from one jurisdiction to another and can change without warning. Gathering updated cost data is time-consuming. Making assumptions about future spending can lead to subjective guesswork.

A new forecasting solution

IP leaders need objective analysis that eliminates complexity and generates reliable budget forecasts. That capability is now available with Forecast from Clarivate.

Designed specifically for legal teams managing large IP portfolios, Forecast provides powerful IP budget forecasting and planning capabilities, seamlessly integrated with Clarivate IP Management Software (IPMS).

Forecast uses sophisticated artificial intelligence (AI) to perform predictive analyses based on portfolio trends using accurate, up-to-date cost data. It provides objective information to improve budget planning, support informed financial decisions and stay ahead of changing conditions.

Transforming budget planning

Easy and intuitive to use, Forecast transforms the IP budgeting process by enabling IP leaders to generate reliable forecasts quickly and efficiently, view costs across their portfolio, with powerful filters to zero in on critical data, and compare actuals to forecasts, helping them stay on track. Analyze data with ease using visual dashboards and custom reports. Assess different scenarios to make informed decisions with a clear understanding of their budget implications.

Forecast provides the next-generation tools IP leaders need to hit their budget consistently while dramatically improving their efficiency and speeding budget approvals.

To get the full Forecast story download our report Transforming IP budget forecasting.

Ready to sharpen your budget forecasting accuracy? To learn more about Forecast, contact Clarivate today.

The post IP cost forecasting: adding accuracy, removing guesswork [New Report] appeared first on Clarivate.

Patient recruitment accounts for 32% of all trial costs and patient drop out averages 18%, according to Deloitte figures. A new Clarivate report: Harnessing the power of RWD in clinical trials, explores how  trial sponsors are thinking more strategically and incorporating real world data into their trials.  

Real World Data

In recent years, the use of real world data (RWD) has emerged as a powerful tool for enhancing clinical site selection. RWD encompasses a wide range of information, including electronic health  records (EHRs), insurance claims data, patient registries, wearable device data, and even social media content.

In addition to clinical data tied to sites and investigators, RWD allows trial sponsors to know which investigators have experience in conducting a clinical trial in their patient population. Importantly, it can help to identify those PIs that are more likely to have access to their specific patient population of interest.

In therapeutic areas where there is competition for trial participants (e.g. oncology), trial productivity is essential. Identifying sites with oncologists and clinical staff that have expertise in treating a specific cancer type is critical. RWD sources such as cancer registries hold a lot of applicable information on the prevalence of specific cancer types, while patient databases and cancer centers’ historical data are valuable sources for understanding the number of eligible patients and their willingness to participate in clinical trials.

In areas such as rare disease, where patients may be few and often unevenly geographically distributed, RWD can help to optimize site feasibility by adding information from EHRs, patient registries, and claims databases to augment transparency around disease prevalence and patient demographics.

Drinking from the firehose

Valuable real world data is abundant but disjointed, being scattered across myriad formats and public and private databases. This poses a huge challenge for effective utilization, especially for small-to-mid-sized companies. Fortunately, numerous entities, including non-profits, consortia and commercial enterprises, are  gathering and centralizing this real-world data, enabling its meaningful application.

These include patient networks such as PatientsLikeMe, the Innovative Medicines Initiative’s EHR4CR project and the Sentinel Initiative, created by the U.S. Food and Drug Administration.

The importance of trusted and robust data sets that can be joined up and used in tandem cannot be overstated. Clarivate’s Cortellis Clinical Trials Intelligence product overlays clinical sites with incidence and prevalence data, allowing trial planners to see epidemiological data in relation to clinical sites.

On top of this, Cortellis Clinical Trials Intelligence has recently incorporated U.S. claims data, meaning that those using this service can analyze site information overlayed with epidemiological data, and from there can access individual site details for a U.S. hospital to see the claims data in the past 12 months. Having access to clinical data with epidemiological and real-world data, all in one offering, can streamline the site selection process.

RWD is transforming the landscape of clinical site selection, offering a data-driven, patient-centric approach to trial planning. By harnessing the power of data, pharmaceutical companies, research institutions, and healthcare organizations can enhance the efficiency, diversity, and relevance of clinical trials, and thereby realize faster drug development, better treatment options, and improved patient outcomes.

The integration of RWD into clinical research is likely to become even more pivotal in shaping the future of medicine. If trial sponsors can access this data in a trusted and layered way, RWD will save dollars and lives, a win-win for all stakeholders in the healthcare ecosystem.

To learn more about the use of RWD to accelerate clinical trials, download the report, Harnessing the power of RWD in clinical trials. You can learn more about the Clarivate Cortellis Clinical Trials Intelligence solution here.

The post Real world data’s role in strategic site selection appeared first on Clarivate.

The Citation Laureates 2023 list has been announced, recognizing a select group of influential, highly cited researchers whose contributions are on par with Nobel Prize recipients. We explore their profound impact on our world and their enduring commitment to the pursuit of knowledge, inspiring the next generation of researchers. 

We at the Institute for Scientific Information (ISI) at Clarivate have announced 23 new Citation Laureates, a designation that recognizes researchers of Nobel class based on citation analysis and suggests that these individuals might one day be called to Stockholm to receive the Nobel Prize itself. In fact, since 2002 when Clarivate began naming Citation Laureates annually, 71 Citation Laureates have gone on to receive Nobel honours.

Identifying the Citation Laureates

The selection of Citation Laureates begins with an examination of highly cited papers in the Web of Science, typically published from 1970 to the present. We focus on papers published 20 to 30 years ago. This time window constitutes something of a sweet spot in terms of Nobel Prize forecasting because the Prize is typically given only after history has shown that a specific research contribution has had an enduring and significant impact.

Of some 58 million papers (articles and proceedings) indexed in the Web of Science since 1970, only about 8,700 have been cited 2,000 times or more (.01%). This is a level of attention that most Nobel Prize winners in Physiology or Medicine, Physics, or Chemistry earn in one or more of their papers. For Economics, the threshold is around 1,000 citations.

In addition to the number of citations, our selection process considers whether the authors of the highly cited papers were the primary discoverers or individuals who extended the work of pioneers – it is the pioneers that have priority in the Nobel Assembly’s choices. We also check if the researchers have been recipients of international or national awards, which may corroborate and reinforce our selection.

We also try to imagine whether the identified achievements might be recognized in terms of the nature of past choices, since the Nobel Committees exhibit a ‘taste’ for some types of discoveries, such as those that have overturned a long-established paradigm.

Finally, we look at recent Nobel Prizes and judge whether the topics identified would likely receive attention within next few years. Although we do not forecast a topic or researchers for the Nobel Prize in the year we name them Citation Laureates, we do try to anticipate near-term awards.

Diverse fields of excellence

The Citation Laureates 2023 represent diverse disciplines, from cancer treatment to designer molecular structures, human microbiomes to synthetic gene circuits, and wealth inequality to urban economics.

Here are some examples of the high-impact work from this year’s Citation Laureates:

• In Physiology or Medicine, we applaud researchers who collectively have played a pivotal role in developing cancer immunotherapy, changing the landscape of treatment and offering new hope to patients.
• In Physics, we celebrate a pioneer whose innovative work led to technologies that have advanced data storage, allowing for smaller, faster, and more energy-efficient electronic devices.
• In the world of Chemistry, we honour Laureates whose groundbreaking research contributed to advancements in drug delivery and nanomedicine.
• And in Economics, we recognize an economist whose influential work across urban development, housing and the economics of cities is helping us address the complex challenges and opportunities that cities face in the modern world.

You can hear their personal stories, along with other recent Citation Laureates’, on our interview video series on our website.

The impact on our world

Citation Laureates 2023 have reshaped the boundaries of human knowledge, pushing the frontiers of what is known and what is possible. And their work has undoubtedly inspired others to embark on their own journeys of discovery.

In the spirit of honouring excellence in research, we extend our heartfelt congratulations to the Citation Laureates 2023 and express our gratitude for their commitment to the pursuit of knowledge.

See who’s been selected as Citation Laureates 2023 and explore the Hall of Citation Laureates on our website.

The post Researchers of Nobel class: Citation Laureates 2023 appeared first on Clarivate.

To commemorate the legacy of Eugene Garfield, founder of the Institute for Scientific Information (ISI), Clarivate is proud to announce the inaugural Eugene Garfield Memorial Lecture. It will be delivered by Dr. Henry Small on September 28th at the International Conference on Science, Technology and Innovation Indicators (STI) in Leiden, Netherlands. Many of the world’s leading scientometric and science policy researchers gather annually at the STI conference, making it the ideal venue to connect the current work of ISI with the legacy of Dr. Garfield and his indelible impact on the scholarly community.

This year marks the 50th anniversary of Dr. Small’s seminal paper, “Co-citation in the scientific literature: A new measure of the relationship between two documents”, published in the Journal of the American Society for Information Science in 1973. Dr. Small famously authored the paper in his first few months at the ISI, under the guidance of Dr. Garfield. He will reflect on the history of co-citation analysis and its early development, under the influence of Eugene Garfield, Thomas Kuhn, and Derek de Solla Price.

As a pioneer in automated indexing and retrieval of information since 1955, Eugene Garfield (1925-2017) developed citation databases for science that changed how researchers search and assess the scholarly literature. Three decades before the invention of the world wide web, Dr. Garfield connected the immense body of scientific knowledge in a network. With the creation of the first Science Citation Index, which is celebrating its 60th anniversary in 2024, he unlocked the power of the citation — the connection between one discovery and another, which was quite literally a “Web of Science.”

The Eugene Garfield Memorial Lecture replaces the Eugene Garfield Award for Innovation in Citation Analysis which was established in 2017. The lecture will be a testament to Dr. Garfield’s lasting impact on the field of citation indexing and analysis, acknowledging the transformative power of his ideas and inspiring future explorations at the frontiers of scientific discovery.

Venue: Special session: Garfield memorial lecture and cocktail reception, September 28th, from 4 – 5.30pm in the Breezaal, Stadsghoorzaal, CWTS, Leiden.

The post Clarivate announces the inaugural Eugene Garfield Memorial Lecture appeared first on Clarivate.

Each year, prior to the G20 Summit of the heads of state of the member nations, the Institute for Scientific Information (ISI) at Clarivate releases its annual G20 scorecard. This condenses and compares the research and innovation capabilities of the G20 economies* which are renowned for their significant investments in education, research and technology. It serves as an indispensable resource for professionals across academia, government and industry – individuals who need to understand shifting global research trends to inform strategic planning, investment and decision-making.

This year for the first time, the G20 scorecard’s extensive dataset is presented in dynamic, interactive charts, with filters to make quick comparisons and deep-dive analyses easier than ever. We’ve also published a downloadable executive summary that distils the key findings for 2023 to reveal the stories behind the data.

Breaking down the data

The G20 scorecard arranges the data into five key categories, with a dropdown filter to allow you to explore in depth:

• Figure 1: Context  – An overview of the people, financial, intellectual property and bibliometric data for all G20 members (e.g. population, GDP, female researchers, patents, academic papers, etc.), highlighting their diversity and giving context for the other data in the scorecard.

• Figure 2: Impact – The citation impact (measured by Category Normalized Citation Impact, or CNCI) of the papers published by each country/region, presented in both an Impact Profile and the trend for 2013-2022.

• Figure 3: Output – Trends in international output and open access output for 2013-2022 for each G20 member nation.

• Figure 4: Disciplines – Charts the output and impact of each G20 member by discipline together with the trends for 2013-2022.

• Figure 5: SDGs – Displays the impact and output of each G20 member linked to each United Nations Sustainable Development Goal (SDG), normalized and benchmarked against the world or G20 average.

Discovering the stories behind the numbers

One of the most interesting aspects of the G20 scorecard is its ability to reveal the unique stories hidden within the data. Let’s take a glimpse into some of the significant findings from the 2023 edition:

• Mainland China’s innovation leap: With a remarkable patent creation record in 2021, Mainland China is catapulting itself into a position of global innovation leadership.
• United States’ research impact conundrum: Despite being a research giant, the U.S. has witnessed declines in CNCI and Collaborative CNCI over the past decade. This trend beckons a closer exploration into the dynamics of research impact and collaboration.
• Argentina’s collaborative influence in medicine: Argentina’s medical research achievements, buoyed by international collaboration, surpass the global average by a remarkable 1.5 times — a testament to the power of global partnership in driving impactful research.
• Brazil’s embrace of OA humanities: Brazil’s emphasis on open access publication in humanities research sets it apart, sparking discussions about knowledge accessibility and the dissemination of research findings.
• Saudi Arabia’s unique research dynamics: With the highest average CNCI among G20 nations, Saudi Arabia’s research contributions shine, although collaborative CNCI experiences a slight dip, underscoring its individual research prowess.
• India’s research trajectory: Despite outpacing Mainland China in population, India’s research output and GDP fall significantly short, sparking questions about resource allocation and potential future trends.
• Canada’s multifaceted research output: Canada’s above-average research output, but below-average OA output, across diverse categories invites conversations about collaboration patterns and access to research findings.
• United Kingdom’s shift in dissemination strategy: With over half of its output published in open access journals, the U.K. signifies a shift in research dissemination and partnership strategies.
• Russia’s research challenges: Low CNCI and Collaborative CNCI scores hint at Russia’s hurdles in research impact and international collaboration.
• Japan’s gender imbalance and research productivity: Japan’s gender imbalance in research and low research productivity raise important questions about structural issues within its research ecosystem.

A vision for informed collaboration and analysis

The dynamic G20 scorecard is poised to become an invaluable tool for planning, investment and collaboration, offering guidance for strategic decision-making across academia, industry and government. The in-depth analyses and dynamic data reveal a panoramic view of the global research landscape, enabling stakeholders to make informed choices and collaborate effectively for the betterment of society.

At Clarivate, we are committed to bringing clarity to the complex. The dynamic format of the G20 scorecard reflects this commitment, providing governments, funders and research institutions with an interactive benchmark for regional research economies. It empowers them to make critical research planning and strategic investment decisions.

Explore the G20 scorecard to understand its data and insights here: https://clarivate.com/the-institute-for-scientific-information/2023-g20-scorecard

You might also like to read our other ISI reports, or contact our team if you’d like to find out more about how we can help evaluate research at your organization.

*Note: The G20 member nations include Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Republic of Korea, Mexico, Russia, Saudi Arabia, South Africa, Türkiye, the United Kingdom, and the United States. The 20th member, the EU, is not part of the scorecard analysis.

The post Gain new perspectives on global research: Unveiling the dynamic G20 scorecard from ISI appeared first on Clarivate.

Awards and reviews

IPfolio received a number of Summer 2023 award badges from G2, a respected source of peer reviews from more than 80 million software users annually. These awards are particularly special because they recognize the benefits most important to our customers, earning the highest rating within its category for usability, ease of use, meeting user requirements, and user adoption. We even won the coveted “Users Love Us” badge, earned by collecting at least 20 reviews with an average of 4 stars.

Speaking of reviews, IPfolio users are not shy about sharing their opinions online. In addition to the glowing reviews on the G2 website, users have given a 4.93 out of 5 star rating on the Salesforce AppExchange. Their reviews highlight not only IPfolio’s ease of use and powerful functionality, but also the top-notch customer service and support that Clarivate provides. One reviewer put it this way:

“IPfolio is smart, nimble and intuitive…the absolute best IP management software around.”

The IPfolio difference

Why does IPfolio inspire such customer loyalty? We believe it comes down to some key user-centric advantages:

• IPfolio is highly configurable, giving customers the flexibility to meet their unique needs—and evolve as those needs change.
• Integrated services. IPfolio offers access to Clarivate’s unmatched breadth of integrated services—from Search through Drafting and Filing to European Patent Validations to Annuities and Recordals.
• Data quality. Extensive data verification and enrichment for Clarivate IP data helps ensure accuracy, consistency and completeness.
• SaaS delivery. Our cloud-based Software-as-a-Service design ensures users always have access to the latest features without time-consuming software updates. Users enjoy secure access anytime, from anywhere with an internet connection.
• Smooth implementation. Best-in-class guidance from the Clarivate in-house professional services team gets users up and running quickly and smoothly.
• Superior customer support. Our dedicated customer success teams are on-hand to support users every step of the way, building partnerships focused on meeting business objectives.

More power on the way

While the G2 awards are gratifying, we’re not resting on our laurels. We are working to continuously improve IPfolio with a host of powerful new features and functionality, including:

• Coming soon: IP cost forecasting with Forecast

Track and predict IP costs across the entire portfolio more accurately and efficiently with our AI powered, next-generation IP forecasting tool, coming soon.

• Advanced Analytics from CRM Analytics

Manipulate, visualize and analyze large data sets faster and more flexibly than ever before with Advanced Analytics from CRM Analytics. Use the Portfolio Explorer feature to visualize categories, drill down for more detail and easily access related information. World Map lets you quickly see where trademarks are registered around the world.

• E-Correspondence

This new functionality extracts documents and bibliographic data from Japan (JP) PTO correspondence packages, saving time and avoiding errors. Integrations with other PTOs are in the works.

To learn more about IPfolio contact us today for a demo.

The post The reviews are in: IP professionals love IPfolio appeared first on Clarivate.

Derwent World Patents Index (DWPI) turns 60 this year. In this blog, Ed White, Senior Director and Principal Analyst, celebrates how DWPI evolved from a newsletter of patent abstracts into an integral part of the global patent system.

With 22 years of experience in the intellectual property industry, Ed White is devoted to helping people capture the right insights from the world’s patent data. Ed has developed new methods of analyzing innovation ecosystems and advised hundreds of corporations, institutions and governments with technology data investigations.

Today, Ed continues to look for new ways to help innovators, strategists and IP professionals use patent data to make more informed decisions. With over two decades spent closely working with Derwent, Ed shares his thoughts on the evolution of DWPI.

Let’s start with a fundamental question. What is the origin story of Derwent World Patents Index (DWPI)?

The origin of DWPI goes back to 1950s London when Derwent’s founder, Montague (Monty) Hyams, was given the job of reporting on patents coming out of his employer’s competition. He quickly discovered it was an incredibly painful undertaking. Patents can be extraordinarily hard to read in a short amount of time making it difficult to find relevant information quickly among a pile of patents. Monty began to summarize patents into short abstracts that would give his employer the information they needed to decide which patents were worth investigating in detail.

At the same time, he discovered that patents published in the United Kingdom were also being published in Belgium — but six months earlier, assuming the patents were co-filed in both countries. He would take a ferry over to the Belgian patent office once a month and write out these abstracts. In doing so, he created the idea that reading one member of the patent family gives you an indication of the rest.

Soon after, Monty started writing a newsletter with his abstracts. Within a few years he had so many subscribers that he went full time. From there, Derwent was born, named after his home where he worked.

Knowing the origin of DWPI, it seems like the name is a misnomer. We emphasize “Index” in the name Derwent World Patent Index, but we don’t mention the word “abstract”. Is there more value in the abstracts or the index?

Within Derwent World Patents Index, the word “index” is used as a synonym for database. Yet, to call DWPI a patent database is an understatement since it’s so much more. It is a database of technical ideas that records where, how and when they were patented. It tells you what was invented, what use that invention is intended to be put towards and, crucially, it tells you why it was invented and the advantage it provides.

To boil the definition down to as few words as possible, DWPI is the great library of human invention.

DWPI has evolved tremendously since its inception. How has it changed over the last 60 years?

The biggest change to DWPI is the sheer scale and pace at which new inventions are being patented. Today, we add almost four million new inventions to DWPI each year. That is around a thousand times more volume than the team was handling at the start. Of course, the capability to handle this data at scale is achievable thanks to the advancements of automation, the incredible editorial processes and the dedication of many experts and technologists.

With large volumes of data, we can apply large-scale statistical analysis and evaluate macro trends in global innovation. We can see how these trends are evolving in different geographical regions. Our annual report, Top 100 Global Innovators, provides a taste of what this analysis can achieve.

Looking at DWPI today, what unique value does it provide?

First and foremost, DWPI categorizes patents by invention family. This greatly deduplicates the number of documents to review. Secondly, our teams read and analyze each invention before summarizing it in a clear and consistent way using standardized language. This allows our clients to review many more inventions than they could otherwise, and it also makes it easier for them to retrieve relevant publications using keyword searches.

We index the world’s inventions so that patent researchers can quickly find those related to a particular technology category. This indexing is unique because it is driven by industry needs and customer feedback. For example, I remember a client that told us how time consuming it was to manually review images to determine if a patent was specific to a front or top load washer. So, we created specific categories for that purpose.

And lastly, we cleanse the data. From spelling mistakes in company names to incorrect classification codes, these little errors create havoc. They can cause researchers to miss relevant inventions when performing patent searches.

For example, when using the International Patent Classification (IPC), G10 and G01 are commonly mistyped. G10 refers to musical instruments and G01 is related to measurement instrumentation. When these get mixed up, our algorithm engines can find the error and flag any misclassifications to an analyst for correction.

Download the DWPI fact sheet: The world’s patent data, curated and simplified

Can you share some of the client projects you’ve worked on across your 20-year career?

My favorite projects are those that have us looking for groundbreaking innovation, like DNA sequences as a data storage.

But the effect our work has is also interesting. For example, we performed a technology scouting exercise for a consumer goods company that ended with surprising results. The customer wanted Clarivate to identify an academic partner that could improve a specific process. Instead, using DWPI, we were able to discover a small company in the United States that was already doing what the client was planning. Six months later, we saw in the news that they acquired the small company, having not been aware of their existence before the scouting exercise.

We also work with governments to help them set and evaluate science and industrial policy based on patent data and analysis. We used DWPI to look at areas within their economy where they likely have research strength and may want to fund more.

Ultimately, these examples center around how we help our customers discover what the community of scientists and engineers already collectively know. Without DWPI, this knowledge stays hidden because it is fragmented deep at that individual, incremental improvement level.

Read the Derwent case study: Establishing a new IP strategic planning group

40 patent offices currently use the Derwent World Patents Index. How has DWPI built up so many patent office subscribers?

Patent offices use DWPI for the same reason that all of our customers do — because of its clarity. DWPI recalls more records more accurately than if you were looking at raw patent data alone. Our patent analysts are skilled at distilling the core features covered in inventions and summarizing these into abstracts which vastly improve precision and recall.

DWPI is truly a systemic part of how the global patent system works. It allows patent offices to access almost every innovation globally in the same language, with a controlled terminology. With DWPI, examiners can find more relevant prior art more quickly. This helps them make better decisions about a patent’s novelty, and review a higher number of applications. In a way, it is difficult to be a patent office without DWPI.

How do you think DWPI will evolve in the future? Are there areas of untapped potential for DWPI?

With advances in AI and language modelling, we will be able to perform new types of predictive analysis about how certain technologies are likely to evolve. All of this potential for AI is available to us because of the countless hours of human intelligence and expertise we have captured from the thousands of technologists that have created DWPI in the last 60 years.

Are there any final thoughts you would like to share about DWPI?

DWPI hitting its 60-year anniversary is a remarkable achievement. It has evolved from a newsletter of patent abstracts into an integral part of the global patent system. This is a testament not just to our product innovation but to our customers as well.

We have customers in 2023 that were subscribing to Monty Hyams’ newsletter in the 1950s and 1960s. These are cherished partners for Clarivate. They have helped us as we’ve helped them. At 60 years of age, DWPI is  the effort of our staff and our customers as they guide us in what to do.

DWPI can help your organization navigate the global innovation landscape. To learn more, visit Celebrating 60 years of DWPI

Ready to try Derwent World Patents Index? Contact us today to explore your options.

The post Celebrating 60 years: Explore the evolution of Derwent World Patents Index appeared first on Clarivate.

Much of the fine print of the sweeping Inflation Reduction Act, signed into law by President Biden last August and in effect since March, is still to be written – though going by the recent final guidance, the broad strokes of the law will not budge. The biopharma industry is sweating the long-term implications and warning that it could mean less lifesaving drugs make it to patients going forward.

The law was top-of-mind at this summer’s ASCO and BIO meetings, tentpole events in the biopharma conference calendar. In one panel discussion at the BIO event, Biogen Head of Corporate Development Adam Keeney said, “I don’t think we should debate a cap on out-of-pocket spending, or that insulin should be appropriately priced for the elderly population that needs it, but it does fundamentally change the way we are approaching investment internally versus externally. We are being forced to think about small molecule versus large molecule and how to get the biggest impact earliest.”

Among the possible knock-on effects:

• Patients will benefit in the near term but could lose out on new drugs in the long term. The law establishes a cap on out-of-pocket drug costs for Medicare patients through the Medicare Part D prescription drug benefit and limits the monthly cost of insulin to $35 for people on the program. Furthermore, it disincentivizes sharp price increases by requiring manufacturers to rebate Medicare when prices rise faster than inflation. It also authorizes the Centers for Medicare and Medicaid Services to negotiate prices for a select list of the drugs most costly to the Medicare Part D prescription drug benefit, the first ten of which are to be announced in September. However, it is likely that new drugs will be priced higher initially because of the law’s inflation rebate mechanism, with developers disincentivized from taking 5-10% annual price increases that many innovative therapeutics have commanded in the past.

• The small molecule pipeline could shrink because the legislation, as currently written, authorizes price negotiations for small molecule drugs within Medicare nine years after initial approval, while biologics get 13 years price control free, post-approval. As biopharmas shift gears towards more large molecule R&D in response (e.g., Pfizer’s $43 billion acquisition of Seagen), a number of therapy areas could be impacted, most notably neurology and cardiology, where small-molecule therapeutics dominate the pharmacopeia. Drug makers could shift their portfolios away from categories and indications with a long ramp-up time to profitability, such as cardiovascular conditions, or those disproportionately impacting elderly Medicare recipients. This shift could prove expensive to health systems, as generally self-administered small molecule drugs give way to more biologics, which often require injections or infusions in a clinical setting, adding costs and raising the risk of nonadherence.

• Market entry strategies will shift. Narrow windows for negotiation-free exclusivity could disincentivize drug development across therapeutic areas, but treatments for oncology and orphan conditions could be particularly hard hit. In addition, companies in these categories have traditionally pursued a “land and expand” strategy of commercialization by first gaining approval for an orphan indication in the U.S., then seeking to broaden the label. The IRA makes this tactic less attractive by shielding orphan indications, but not potential follow-on indications, from price negotiations and starting the clock at that initial approval, potentially forcing developers to reprioritize.

“You want that initial approval to be the most lucrative possible indication, because the clock is ticking,” said Mickey Popli, Director of Consulting Services at Clarivate. “That puts patients with rare diseases at a disadvantage, because manufacturers may delay or abort launches for those indications.”

Furthermore, oncology drugs typically win initial approvals for late-line treatment and gradually expand into more lucrative (and often more effective) use to treat earlier-stage patients, dealing developers a double hit.

• R&D efficiency is more critical than ever. With profitability constrained, pharmas will seek to make up lost ground by getting leaner and meaner and making better go-no-go decisions early in the R&D process.

“I think we’ll see a lot more companies cutting bait when it comes to clinical trials,” said Bill Melville, Lead Healthcare Research and Data Analyst at Clarivate. “Failing fast and not plowing resources into later-stage development is going to be the goal.”

The vise on revenues also makes differentiation essential.

“The companies that are developing me-too products will not benefit,” said Mike Ward, Global Head of Thought Leadership at Clarivate. “The future equivalent of the 7^th triptan or the 8^th PD-1 will not command high prices. Therefore, you need to understand what’s going to be hot and, should you take a candidate into clinical trials, how to make them more effective.”

In the long run, pharmas and biotechs will have to sit down with governments and make the case for paying for innovation. In the meantime, pharmas will need to make tough decisions while nurturing the pipelines of tomorrow.

“You may see a promising product in Phase 1, Phase 2, but if the opportunity is not there and you don’t spend that money, the product will die,” said TD Cowen Senior Biotechnology Analyst Ritu Baral at the BIO panel.

“Pharma has to play a role in maintaining a healthy ecosystem,” agreed Biogen’s Keeney. “The challenge with the IRA is that we as an industry have lost the argument around value. We have to change that dynamic to protect the contribution we provide to society.”

To learn more about how Clarivate helps biopharma companies optimize their commercial launch strategies, please visit us here. You can find information on Clarivate market access intelligence offerings here.

The post Four key points on the Inflation Reduction Act appeared first on Clarivate.

We’re incredibly excited about this next step in our union and would like to reassure our customers that we are here to support you.  While we have a new look, our commitment to you remains the same. In fact, our combined expertise, data and technologies are already helping customers make smarter and faster evidence-based decisions enabling the delivery of safe, effective, and commercially successful solutions faster. We are also taking stock of this opportunity to enhance our approach and service for a more unified and consistent brand experience for our valued customers.

How this supports our mission to help you drive innovation

Dialog’s technology and services, combined with our unrivalled access to the world’s best academic literature databases, make research more powerful and efficient. The integration with Dialog has further strengthened Clarivate as a leading global provider of information and insights that can accelerate the innovation cycle, bolstering a robust, integrated platform of life science intelligence solutions that support the entire drug development lifecycle.

As an organization centred on innovation and transformation, our products and services are imagined, created, and improved in a continuous, connected lifecycle of innovation: discover, protect, commercialize.  Our mission is to help customers solve some of the world’s most complex problems and reduce the time from idea generation to implementation. Migrating the Dialog brand to Clarivate supports our mission, enabling users to benefit from more integrated solutions and ultimately accelerates innovation and commercial efforts for customers.

Q: How this affects you, our valued customer

A: Below we’ve outlined answers to any immediate questions that may arise from this transition. Should you have further questions, please reach out to your account manager or email dialog.support@clarivate.com

Q: Is there anything I need to do as a customer in light of this transition?

A: No, we will inform customers ahead of time if any action is required on their part as we continue with the integration. We are excited to leverage our combined solutions to deliver greater value to our customers.

Q: Will my key contact change?   

A: At this time, we do not expect changes to key contacts. However, if there are changes to your key contacts, you will hear directly from your account manager or our customer support teams.

Q: How will this affect my access to products and services?   

A: Clarivate and Dialog have complementary and synergistic product portfolios that, when combined, will enable us to support the drug, device and medical technology landscape from research through to outcome. We are building a unified product strategy that will deliver innovative solutions leveraging our complete set of data and capabilities. This will be achieved via highly specialized analytics and unique expert insights. Over the coming months, you may notice changes to the names of some of the products or to their look and feel as continue to unite under a singular brand.

The post Dialog Solutions becomes Clarivate appeared first on Clarivate.

Scientific research is increasingly collaborative. The once siloed approach to research activity has given way to a more interconnected global model, which has enabled a global research network to evolve. For many research economies and groups, international collaboration now accounts for  more academic publications, than purely domestic output. Institutions that do not form international collaborations risk disenfranchisement.

Deciphering the trends in research funding

Staying up to date is made easier by following reports and events that examine the ebb and flow of research funding and provide insights into the priorities and strategies of major funding organizations. An example is the Funding Trends Report published annually by Research Professional News. This year the report was matched with a virtual panel discussion that explored the nuances of working with organizations such as the Bill and Melinda Gates Foundation, the U.S. National Science Foundation, and the Australian National Health and Medical Research Council, some of the world’s largest research funding agencies. During the panel discussion, guest speakers Adam Golberg, research development manager at the University of Nottingham, and Lorna Wilson, director of research development and operations at Durham University provided broader tips for international research collaboration. (see box)

A key take-away: the massive budgets of these funders belie a challenging reality. Despite a steady increase in overall funding budgets, the actual size of individual grants and success rates have remained relatively stagnant, indicating a complex and fiercely competitive funding landscape.

Mastering the art of securing funding

Securing research funding from major organizations requires a deep understanding of the unique goals and requirements of each one. The Gates Foundation, for instance, is known for its directive funding approach. Researchers accustomed to a high degree of autonomy may find themselves receiving more specific guidance regarding the direction of their projects, according to the discussion in the event. This hands-on approach may determine whether the Gates Foundation is the right fit for a particular project.

Conversely, the Wellcome Trust is currently working toward diversifying its recipients. Researchers with ideas centered around health and wellbeing may find the Wellcome Trust an attractive option. The organization’s recent outreach efforts across the U.K. and its webinars aimed at researchers and institutions in Latin America, Africa and Asia signal a clear intent to broaden their funding recipients.

Facing the challenges in securing funding

Rising competition and the need for a robust delivery plan pose significant hurdles for researchers. Partnerships assembled hastily often falter when it comes to securing large grants, particularly in the face of competition from teams with a long-term history of collaboration. Funders and assessors are increasingly interested in the track record of a team and its ability to deliver the project, further raising the bar for successful bids.

Pursuing equitable partnerships

In the context of research partnerships between the Global North and Global South, the quest for equity is a pressing concern. Power imbalances, resource hoarding and a lack of inclusivity in research are detrimental traits that often hinder the success of international partnerships.

Attendees at the event learned that to foster more equitable collaborations, it’s crucial to hold discussions with partners early and to maintain a focus on the research itself rather than the allure of funding. Ensuring fair recognition of contributions and providing opportunities for leadership roles can go a long way in establishing authentic relationships and promoting inclusivity.

Charting the course for future scientific endeavors

The challenges for scientific research endeavor in the 21st century are significant, from the fierce competition for funding to the need for robust delivery plans and long-standing collaborations. Yet, these challenges are not insurmountable. With strategic acumen, a deep understanding of funding organizations and a commitment to fostering equitable partnerships, researchers can unlock new avenues for funding and collaboration.

Moreover, the pursuit of equity in research partnerships, particularly between the Global North and Global South, is not just a moral imperative but a strategic one. Equitable partnerships can lead to more innovative and impactful research, benefiting not just the partners involved but the global scientific community.

As we grapple with the complex challenges facing humanity, from climate change to global health crises, the role of international research collaborations will be pivotal. These collaborations will drive the scientific advancements needed to confront these challenges and propel societal development.

The journey through the global research funding landscape may be complex, but the potential rewards – groundbreaking discoveries, scientific growth and societal progress – are immense and worthy of our collective effort.

Clarivate can help you implement confident, evidence-informed strategies to drive research excellence. Get in touch  with our experts to learn more.

The post Navigating research challenges through collaboration and Equity appeared first on Clarivate.